hotspot -WSS

hotspot

author：hotspot 2025-09-02 08:19:32 - browse：6166

Cambridge: Biogen — Ruby Wallau for STAT

Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a new acquisition.

The Cambridge, Mass., drugmaker announced Wednesday that it will acquire Human Immunology Biosciences, or HI-Bio, for $1.15 billion and up to $650 million in additional payments if certain milestones are met.

HI-Bio, which is based in San Francisco, is developing therapies for immune-mediated diseases like primary membranous nephropathy and IgA nephropathy, both of which impact kidney function. The startup’s lead drug, felzartamab, is a monoclonal antibody that selectively depletes CD38+ and natural killer cells in the hopes of alleviating the disease’s effects. It has already completed Phase 2 studies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： How dance can help nurses traumatized by Covid

leisure time

entertainment

WSS

Group opposing PBM reform sets lobbying record

At Orexo, a ‘turning point’ for everything but digital health

Megan Rapinoe shares emotional post following US Women's World Cup exit

Dozens dead from Maui wildfires: What we know about the victims

Group opposing PBM reform sets lobbying record

Novo Nordisk touts Wegovy study, but still struggling with supply

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Activists slam private health insurers over coverage restrictions

Maui wildfire now ranks as the fifth

DIEP, the 'gold standard' of breast reconstruction, is under threat

Key House panel plots a new health care package

Alkermes shareholders re

Senators push IRS to launch nonprofit hospital probe

Alkermes shareholders re

Aspartame and sugar

Medical leaders decry Supreme Court decision on affirmative action

Novo Nordisk touts Wegovy study, but still struggling with supply

entertainment

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

Judge sides with young activists in first

FDA approves RSV monoclonal antibody for infants, toddlers

Cosmetics set for new safety regulation. Why the industry is on board

Key House panel plots a new health care package

Wikipedia

entertainment

explore

focus